ERBB2 amplification and over-expression in HNSCC confer treatment resistance to cetuximab [41], and its protein product HER2 normally dimerizes with HER3 to bind PI3K and activate the pathway [42]. Here, PIK3CA is linked to head and neck squamous cell carcinoma.